Dr. Julie Johnson is dean of the University of Florida College of Pharmacy and distinguished professor of Pharmacy and Medicine. Her research focuses on cardiovascular pharmacogenomics and genomic medicine implementation. Dr. Johnson is an internationally-recognized leader in pharmacogenomics and genomic medicine, with over 300 peer reviewed publications and nearly $50 million in research funding as principal investigator.
Areas of Expertise (5)
High Blood Pressure Treatment
Warfarin Dosing in Patients With CYP2C9*5 Variant AllelesClinical Pharmacology & Therapeutics
Kathryn J. Lindley, et al.
Pharmacogenetic dosing improves the accuracy of warfarin dosing, but current pharmacogenetic dosing algorithms are less accurate in populations of African ancestry. The cytochrome P450 2C9*5 (CYP2C9*5) allele is found almost exclusively in populations of African ancestry, and in vitro studies suggest CYP2C9*5 is associated with reduced clearance of warfarin.
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 UpdateClinical Pharmacology & Therapeutics
Craig R. Lee, et al.
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events.
A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain managementGenetics in Medicine
Cameron D. Thomas, et al.
Cytochrome P450 2D6 (CYP2D6) genotype–guided opioid prescribing is limited. The purpose of this type 2 hybrid implementation-effectiveness trial was to evaluate the feasibility of clinically implementing CYP2D6-guided postsurgical pain management and determine that such an approach did not worsen pain control.